P4, N=78, Recruiting, Instituto Mexicano del Seguro Social

P=N/A, N=165, Not yet recruiting, Fujian Medical University Union Hospital

Subcutaneous schwannomas of the skin (CS) are common in the NF2 population.This trial involves the repurposing of medications already licensed for HIV-ritonavir and lopinavir (Kaletra and Norvir)-that have been shown to reduce tumour growth by reducing cell proliferation in human schwannoma and meningioma tumour cell cultures...Following analysis of trial data, the trial results will be written up for publication in a peer-reviewed scientific journal and will be disseminated at conferences. ISRCTN10422213.

Adults living with untreated HIV-1 were randomized (1:1) to a DOR-containing regimen or comparator (darunavir/ritonavir- or efavirenz-containing), each with 2 nucleos(t)ide reverse transcriptase inhibitors, for 96 weeks (double-blind base), followed by 96 weeks of a DOR-containing regimen (open-label extension). Clinical Trials Registration.  ClinicalTrials.gov NCT02275780, NCT02403674.

The topoisomerase I inhibitor payload (DXd) released from the human epidermal growth factor receptor 2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) is eliminated by hepatic uptake via OATP1B1/3, metabolism by CYP3A, biliary excretion via P-glycoprotein and breast cancer resistance protein, and urinary excretion. DDIs with ritonavir and itraconazole simulated by the PBPK model reproduced the clinical DDI study results, indicating that the impact of concomitant medications was not clinically meaningful. These findings suggest that this model may potentially be used for DDI evaluation of future DXd-containing ADCs, aiding in the prediction of DDIs under different scenarios and in specific populations.

P2, N=40, Active, not recruiting, Federal University of São Paulo | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Nov 2026

P2, N=118, Not yet recruiting, Daré Bioscience, Inc.

Intraoperative UTI attenuates postoperative CRP and ALT elevation, reflecting anti-inflammatory and partial hepatoprotective effects. Integration of UTI into comprehensive perioperative management may enhance clinical recovery.

P1, N=21, Recruiting, University of Wisconsin, Madison | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

P1/2, N=76, Recruiting, Medical University of South Carolina | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: May 2026 --> May 2027

P=N/A, N=350, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o

P=N/A, N=1370, Not yet recruiting, Beijing Tiantan Hospital